Choo E F, Angus P W, Morgan D J
Department of Pharmaceutics, Victorian College of Pharmacy, Monash University, Melbourne, Australia.
J Hepatol. 1999 Mar;30(3):498-502. doi: 10.1016/s0168-8278(99)80111-1.
BACKGROUND/AIMS: There is evidence to suggest that not all pathways of drug metabolism are similarly affected in cirrhosis. The effect of cirrhosis on drug oxidation and glucuronidation has been extensively investigated but little is known of the effect of cirrhosis on drug sulphation. The aim of this study was to investigate the effect of cirrhosis on sulphation.
We investigated the effect of cirrhosis on p-nitrophenol sulphation and compared this with the effect of cirrhosis on p-nitrophenol glucuronidation as well as on d-propranolol oxidation simultaneously in the single-pass isolated perfused rat liver. The perfusate contained added inorganic sulphate to maximise production of p-nitrophenol sulphate.
About 77% and 59% of p-nitrophenol was eliminated as the sulphate conjugate by the healthy (n=6) and cirrhotic (n=7) livers, respectively. Mean total p-nitrophenol clearance was decreased in cirrhosis (healthy: 18.5+/-0.2 vs. cirrhotic 15.3+/-4.0 ml/min; p<0.05). The decrease in total clearance of p-nitrophenol was due solely to the decrease in sulphate formation clearance, which was significantly decreased (healthy: 14.1+/-1.9 vs. cirrhotic: 9.27+/-3.33 ml/min; p<0.05). Mean glucuronide formation clearance (healthy: 5.11+/-0.94 vs cirrhotic: 5.79+/-0.85 ml/ min; p>0.05) was not significantly altered. Mean total propranolol clearance was decreased in cirrhosis (healthy: 19.9+/-0.1 vs. cirrhotics: 18.0+/-1.5 ml/min; p<0.05).
We have shown that in cirrhosis there is significant impairment of drug oxidation and sulphation, whilst glucuronidation is spared. The decreased sulphation of p-nitrophenol was most likely due to a decrease in phenol sulphotransferase and/or decrease in cofactor synthesis.
背景/目的:有证据表明,在肝硬化中并非所有药物代谢途径都会受到同样的影响。肝硬化对药物氧化和葡萄糖醛酸化的影响已得到广泛研究,但对肝硬化对药物硫酸化的影响却知之甚少。本研究的目的是调查肝硬化对硫酸化的影响。
我们在单通道离体灌注大鼠肝脏中,研究了肝硬化对对硝基苯酚硫酸化的影响,并将其与肝硬化对对硝基苯酚葡萄糖醛酸化以及对d-普萘洛尔氧化的影响进行了比较。灌注液中添加了无机硫酸盐,以使硫酸对硝基苯酚的产量最大化。
健康肝脏(n = 6)和肝硬化肝脏(n = 7)分别有约77%和59%的对硝基苯酚以硫酸盐结合物的形式被清除。肝硬化时对硝基苯酚的平均总清除率降低(健康组:18.5±0.2与肝硬化组15.3±4.0 ml/min;p<0.05)。对硝基苯酚总清除率的降低完全是由于硫酸盐形成清除率的降低,而硫酸盐形成清除率显著降低(健康组:14.1±1.9与肝硬化组:9.27±3.33 ml/min;p<0.05)。葡萄糖醛酸苷形成清除率平均值未显著改变(健康组:5.11±0.94与肝硬化组:5.79±0.85 ml/min;p>0.05)。肝硬化时普萘洛尔的平均总清除率降低(健康组:19.9±0.1与肝硬化组:18.0±1.5 ml/min;p<0.05)。
我们已经表明,在肝硬化中药物氧化和硫酸化有显著损害,而葡萄糖醛酸化未受影响。对硝基苯酚硫酸化的降低很可能是由于苯酚磺基转移酶的减少和/或辅因子合成的减少。